6 Ways to Elevate Your Machine Translation Strategy

Future-proof your MT strategy for clinical and regulatory content with this guide.

AI Driven

With 2025 well underway, innovators in the global life sciences and pharmaceutical industries continue to question how to maximize efficiencies and reduce complexities in clinical and regulatory content development and localization. As part of the broader technological roadmap, AI and automation remain front and center as key players in taking these workflows to new heights. Here are six approaches to ensure you don’t miss a pivotal step when adapting and applying your process.

translation_factory

1. Translation Model Customization

The pharmaceutical industry commands precision and optimal quality in all content. MT models should therefore be tailored and regularly updated such that they align with industry-specific terminology and have built-in glossaries that enforce accuracy and consistency across all translated materials. Using translation memories (TMs) and engine customization with company-specific data enables teams to repurpose pre-approved translations to cut down on review cycle times and ensure content uniformity when compared to “off-the-shelf” machine translation models.

Learn more about how machine translation drives success ›

2. Integration with Clinical & Regulatory Technologies

From a workflow perspective, MT can be integrated directly into additional content repositories, like an eTMF, RIM, web CMS, and more. This generates faster and more secure MT workflows that can be initiated from those same systems where your documents are authored and stored, in a secure “closed loop” ecosystem. In addition, integration with technologies like generative AI and natural language processing can yield more sophisticated language understanding and translation than MT alone. Explore 5 essential use cases for AI automation in regulatory content.

clinical_practice
contact

3. Increased Use of Multimodal Translation

With continually evolving capabilities and new use cases being identified, MT may extend beyond text to include multimodal elements, such as translating audio, images, graphs, and other visual content commonly found in pharmaceutical documents. This could enhance the overall translation of complex information and provide significant efficiencies in areas like patient recruitment and medical information, which more frequently utilize multi-channel and non-document-based content.

4. Enhanced Post-Editing Automation

Automation of post-editing processes has become more sophisticated, mitigating the need for extensive human intervention post-MT. Generative AI tools embedded within the review module leveraged by post-editors results in more streamlined workflows and rapid delivery of high-quality, fully reviewed translations.

post_editing
Forrester TEI GlobalLink for Life Sciences

5. Compliance Monitoring and Reporting

MT systems have evolved to incorporate multifaceted tools, such as built-in compliance monitoring features, ensuring that translations comply with specific regulatory requirements through automated checks for terminology consistency and language compliance, for example.

Key steps for regulatory submissions ›

6. Real-Time Collaboration Tools

The integration of real-time collaboration tools within MT platforms enhances efficiency and enables global teams to work simultaneously on translation projects. Features like live editing, instant feedback, and collaborative workflows help cut down the time needed to make documents submission-ready.

discussion regulatory

Additional Resources & Expert Perspectives

How to Select the Right Regulatory Writing Company for Your Organization's Needs

Blog

In a landscape defined by ever-evolving global guidelines from health authorities, many life sciences organizations’ clinical and regulatory teams face challenges in navigating the regulatory affairs writing and document submission process. Adhering to strict rules while balancing the concerns of multiple stakeholders, timelines, and costs can be a profoundly complex undertaking in this high-stakes environment. To successfully expand their products globally and ...

How to Select the Right Regulatory Writing Company for Your Organization's Needs
Guide

Governing AI for Global Content in the Life Sciences Industry

AI is already shaping the content that reaches patients, healthcare professionals, and regulators, often through tools that were never built for regulated use. But adoption alone doesn’t create control, and a single terminology error or untraceable approval can put compliance and ...
Blog

MDR SSCPs and IVDR SSPs Are NOT Labeling: What That Means for Your EUDAMED Upload

As soon as possible, but no later than March 27, 2027 (per MDCG 2026-4), medical device manufacturers must upload their validated, translated Summaries of Safety and Clinical Performance (SSCPs) to EUDAMED themselves. IVD manufacturers have the same responsibility for their...
Webinar

Reddit Stories: AI Failures in Clinical Trials

Clinical operations experts react to real AI failure stories pulled directly from Reddit and work backward to identify what should have caught them. From hallucinated citations that passed an initial review to AI-drafted guidance sent to a site without proper oversight, each ...
Blog

Are Legacy COA Instruments Still Fit for Purpose?

The following insights are synthesized from TransPerfect LifeSci Talks, hosted by Mark P. Wade, Practice Leader COA SME at TransPerfect Life Sciences, with guest Kathrin Fischer, PhD, Patient-Centered Outcome Strategy Lead at Boehringer Ingelheim and board member of ISOQOL....
Webinar

The Human in the Vault: Building Review Workflows That Satisfy Regulators

AI translation is already fast enough for most teams. The gap is on the review side: who signs off, what gets logged, and whether the process holds up when a regulator asks. This session walks through a real human review workflow within an AI-assisted translation process ...
Blog

eConsent: Why the Content Matters as Much as the Tech

Insights from a conversation with Edwin Cohen, Principal Consultant / Owner at C&Flow Instrument Creation and Mark P Wade Global Practice Leader & COA SME, TransPerfect Life Sciences For all the attention paid to the systems, platforms, and integrations behind...

Reach out to our team of AI and MT experts to get started today.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.